Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial
- 1 August 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 161 (2), 435-443
- https://doi.org/10.1111/j.1365-2133.2009.09145.x
Abstract
Colonization with Staphylococcus aureus in atopic dermatitis (AD) is often associated with worsening of clinical symptoms. Staphylococcus aureus produces superantigens that contribute to cutaneous inflammation and corticosteroid (CS) resistance. To investigate the relationship between CS insensitivity, S. aureus colonization and superantigen production in AD, and to explore the efficacy of pimecrolimus cream in CS-insensitive AD. This was a randomized, double-blind, vehicle-controlled, multicentre, parallel-group study. Seventy-three patients with AD, aged 2-49 years, who had a documented clinical insensitivity to topical CS, were recruited. The primary efficacy parameters combined laboratory (including S. aureus colonization, superantigens) and clinical assessments [including Eczema Area and Severity Index (EASI), whole body Investigator's Global Assessment (IGA), pruritus assessment score, patient's assessment score of disease control]. An increase in S. aureus counts correlated with worsening of clinical score (week 6 vs. baseline) when assessed by IGA, pruritus severity and patient assessment. The presence of superantigens correlated with this worsening. During the 6-week double-blind phase, disease improvement in the pimecrolimus cream group was demonstrated by decreasing EASI scores compared with vehicle. Mean EASI scores for the head and neck showed greater improvement in the pimecrolimus cream group than in the vehicle group at all observed time points. In a cohort of patients with clinical insensitivity to CS there was a significant positive correlation between S. aureus and disease severity. Results suggest that for some of these patients, treatment with pimecrolimus cream 1% is useful, especially in the head/neck area.Keywords
This publication has 19 references indexed in Scilit:
- Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibioticsAnnals of Allergy, Asthma & Immunology, 2007
- Cytokines and chemokines orchestrate atopic skin inflammationJournal of Allergy and Clinical Immunology, 2006
- Skin colonization byStaphylococcus aureusin patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trialBritish Journal of Dermatology, 2006
- Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathwayJournal of Allergy and Clinical Immunology, 2004
- Abnormal steroid responsiveness in atopic dermatitis patients: therapeutic implicationsAnnals of Allergy, Asthma & Immunology, 2000
- Induction of corticosteroid insensitivity in human PBMCs by microbial superantigensJournal of Allergy and Clinical Immunology, 2000
- Localization of a site on bacterial superantigens that determines T cell receptor beta chain specificity.The Journal of Experimental Medicine, 1993
- Mutations defining functional regions of the superantigen staphylococcal enterotoxin B.The Journal of Experimental Medicine, 1992
- Co-operative double-blind trial of an antibiotic/ corticoid combination in impetiginized atopic dermatitisBritish Journal of Dermatology, 1976
- Staphylococcus aureus in the lesions of atopic dermatitisBritish Journal of Dermatology, 1974